CIRT - CIRSE Registry for SIR-Spheres Therapy
Radioembolisation is a rapidly growing treatment modality in Europe. Although data on the safety and efficacy of this procedure for the treatment of primary and secondary liver tumours is available, more evidence on the treatment in a clinical setting is necessary. Therefore, CIRSE initiated a registry that enables robust data collection on the real-life clinical application of SIR-Spheres microspheres: the CIRSE Registry for SIR-Spheres Therapy (CIRT).
The CIRSE Registry for SIR-Spheres Therapy (CIRT) is a European-wide registry that aims to prospectively collect data on SIR-Spheres therapies. Various European medical centres already use this therapy to treat liver tumours. The registry aims to investigate the real-life application of SIR-Spheres microspheres on a multinational scale.
Primary end point
The primary objective is to observe the real-life clinical application of SIRT with SIR-Spheres Y-90 resin microspheres and the impact of the treatment in clinical practice. Patients will be classified according to the following categories:
- Type of liver cancer
- Intention of treatment
- Prior hepatic procedures
- Associated systemic therapy
- Post-SIRT hepatic procedures
Secondary end points
In addition to observing the real-life application of CIRT, the Steering Committee is also very interested in data on the safety and effectiveness of the treatment. Furthermore, to observe the palliative aspect of SIRT, a quality of life questionnaire has been included in the study.
- adverse events
- overall Survival (OS)
- progression free survival (PFS) by investigator
- liver specific PFS by investigator
- imaging response
Quality of life
- measured with EORTC’s QLQ-C30 with HCC module
Data is being collected prospectively from medical centres in Europe via an electronic data capture (EDC) system. A certain level of experience with SIR-Spheres was required from participating centres in order to exclude operators that are still in the learning phase of the procedure.
As of 1 June 2017, hospital participation has been closed in order to give hospitals time to enrol a sufficient number of patients. 31 December 2017 marked the end of the three-year patient enrolment period. 1051 patients have been enrolled into the registry. Follow-up inclusion will be done until 31 December 2019.
|José Ignacio Bilbao (chairperson)||Clínica Universidad de Navarra/ES|
|Dirk Arnold||Asklepios Klinikum Hamburg/DE|
|Roberto Cianni||Azienda Ospedaliera San Camillo Forlanini/IT|
|Samer Ezziddin||Universitätsklinikum des Saarlandes/DE|
|Thomas Helmberger||Klinikum Bogenhausen/DE|
|Frank Kolligs||Helios Klinikum Berlin-Buch/DE|
|Geert Maleux||Universitair Ziekenhuis Leuven/BE|
|Derek Manas||Freeman Hospital/UK|
|Graham Munneke||University College London/UK|
|Olivier Pellerin||Hôpital Européen Georges-Pompidou/FR|
|Jean Pierre Pelage||CHU de Caen/FR|
|Bora Peynircioglu||Hacettepe Üniversitesi Tıp Fakültesi/TR|
|Bruno Sangro||Clínica Universidad de Navarra/ES|
|Niklaus Schäfer||CHUV-Lausanne University Hospital/CH|
|Ralph Peters||non-voting representative from Sirtex Medical|